Skip to main content

7 Result(s)

within Peter Paschka Remove this filter

and

  1. Article

    Open Access

    Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)

    Mridul Agrawal, Peggy Schwarz, Benedetto Daniele Giaimo, Ivan Bedzhov… in Leukemia (2020)

    Download PDF (703 KB) View Article

  2. Article

    Open Access

    Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)

    BRCA1/BRCA2-containing complex 3 (BRCC3) is a Lysine 63-specific deubiquitinating enzyme (DUB) involved in inflammasome activity, interferon signaling, and DNA damage repair. Recurrent mutations in BRCC3 have bee...

    Tatjana Meyer, Nikolaus Jahn, Stefanie Lindner, Linda Röhner, Anna Dolnik… in Leukemia (2020)

    Download PDF (1709 KB) View Article

  3. Article

    Open Access

    Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

    Mutations in the nucleophosmin 1 (NPM1) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of NPM1 mutated (NPM1mut) AML, we assess ...

    Sibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer… in Nature Communications (2019)

    Download PDF (1255 KB) View Article

  4. No Access

    Article

    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

    In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation che...

    Peter Paschka, Richard F Schlenk, Daniela Weber, Axel Benner, Lars Bullinger… in Leukemia (2018)

  5. No Access

    Article

    Precision oncology for acute myeloid leukemia using a knowledge bank approach

    Peter Campbell, Hartmut Döhner and colleagues present an analysis of genetic mutations and clinical information from 1,540 patients with acute myeloid leukemia, demonstrating the utility of clinical knowledge ...

    Moritz Gerstung, Elli Papaemmanuil, Inigo Martincorena, Lars Bullinger… in Nature Genetics (2017)

  6. No Access

    Article

    The genomic landscape of core-binding factor acute myeloid leukemias

    Lars Bullinger, **ghui Zhang, Jeffery Klco, James Downing and colleagues report a detailed genomic analysis of pediatric and adult core-binding factor acute myeloid leukemias (CBF-AMLs). They identify recurre...

    Zachary J Faber, **ang Chen, Amanda Larson Gedman, Kristy Boggs… in Nature Genetics (2016)

  7. No Access

    Chapter

    Monitoring of Residual Disease in Patients with Chronic Myelogenous Leukemia Using Specific Fluorescent Hybridization Probes for Real-Time Quantitative RT-PCR

    In many ways, chronic myelogenous leukemia (CML) serves as a paradigm for the utility of molecular methods to diagnose malignancy or to monitor patient response to therapy [1]. CML constitutes a clinical model...

    PD Dr. Andreas Hochhaus, Michael Emig, Andreas Weisser… in Rapid Cycle Real-Time PCR (2001)